Avego BioScience Capital

Avego BioScience Capital focuses on mid-to-late stage venture financings for biotech companies, partnering with leading biotech companies at pivotal stages of drug development to help advance promising therapies through clinical trials. The strategy is evidence-based, with a strong preference for proprietary technologies representing genuine scientific advances — prioritizing therapeutics, medical devices, tools, and diagnostics across modalities including gene therapy/gene editing, cell therapies, biologics, and small molecules, with a focus on oncology, neurology, immunology, ophthalmology, and rare disease. Ideal portfolio companies have 'best- or first-in-class' potential, strong IP protection, and proven management teams with public company experience and prior successes in product development.